Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OTLK | Outlook Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-0.25 Insider Own0.80% Shs Outstand256.88M Perf Week-7.87%
Market Cap57.69M Forward P/E- EPS next Y-0.11 Insider Trans-19.10% Shs Float127.42M Perf Month-83.44%
Income-60.30M PEG- EPS next Q-0.06 Inst Own10.70% Short Float / Ratio20.92% / 4.79 Perf Quarter-87.89%
Sales- P/S- EPS this Y10.60% Inst Trans-2.65% Short Interest26.66M Perf Half Y-79.66%
Book/sh-0.02 P/B- EPS next Y56.00% ROA-127.20% Target Price2.50 Perf Year-83.10%
Cash/sh0.12 P/C1.71 EPS next 5Y- ROE-818.70% 52W Range0.20 - 2.03 Perf YTD-80.60%
Dividend- P/FCF- EPS past 5Y52.80% ROI- 52W High-89.68% Beta0.80
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin- 52W Low4.65% ATR0.07
Employees17 Current Ratio0.90 Sales Q/Q- Oper. Margin- RSI (14)21.28 Volatility5.93% 10.35%
OptionableNo Debt/Eq- EPS Q/Q-1.20% Profit Margin- Rel Volume0.61 Prev Close0.22
ShortableYes LT Debt/Eq- EarningsAug 14 BMO Payout- Avg Volume5.57M Price0.21
Recom2.50 SMA20-56.67% SMA50-81.93% SMA200-82.66% Volume3,421,062 Change-2.74%
Date Action Analyst Rating Change Price Target Change
Aug-31-23Downgrade H.C. Wainwright Buy → Neutral $5 → $1
Aug-31-23Downgrade Chardan Capital Markets Buy → Neutral
Aug-30-23Downgrade Guggenheim Buy → Neutral
Aug-30-23Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23Downgrade Cantor Fitzgerald Overweight → Neutral $4.50 → $1
Aug-30-23Downgrade BTIG Research Buy → Neutral
Jul-13-23Initiated CapitalOne Overweight $5
Apr-03-23Initiated Guggenheim Buy $5
Feb-06-23Initiated Cantor Fitzgerald Overweight $4
Oct-31-22Initiated BTIG Research Buy $7
Apr-22-19Initiated Ascendiant Capital Markets Buy
Sep-21-23 08:05AM
Sep-05-23 08:05AM
Aug-31-23 10:15AM
Aug-30-23 06:11AM
11:47AM Loading…
Aug-28-23 11:47AM
Aug-14-23 09:55AM
Aug-01-23 08:45AM
Jun-11-23 08:45AM
Jun-06-23 01:59PM
May-15-23 08:05AM
Apr-27-23 08:05AM
Apr-10-23 11:43AM
Mar-13-23 07:00AM
08:05AM Loading…
Feb-14-23 08:05AM
Feb-07-23 08:05AM
Jan-19-23 08:05AM
Jan-11-23 01:00PM
Jan-09-23 08:05AM
Jan-02-23 07:31AM
Dec-29-22 09:05AM
Dec-23-22 09:00AM
Dec-22-22 08:05AM
Dec-01-22 08:05AM
Nov-22-22 08:05AM
Nov-01-22 09:55AM
Oct-28-22 08:05AM
Oct-05-22 06:09AM
08:05AM Loading…
Sep-27-22 08:05AM
Sep-26-22 08:35AM
Sep-07-22 08:05AM
Aug-30-22 09:39AM
Aug-15-22 08:05AM
Aug-10-22 08:05AM
Aug-04-22 08:05AM
Jul-26-22 07:18AM
Jul-05-22 08:05AM
Jun-14-22 08:05AM
May-31-22 08:05AM
May-27-22 07:25AM
May-18-22 08:05AM
May-13-22 08:05AM
May-10-22 08:35AM
May-09-22 08:35AM
May-04-22 12:02PM
Apr-22-22 08:05AM
Apr-05-22 08:05AM
Apr-04-22 07:45PM
Mar-31-22 08:05AM
Mar-03-22 08:05AM
Feb-24-22 08:05AM
Feb-16-22 10:59AM
Feb-14-22 08:05AM
Feb-10-22 08:05AM
Feb-08-22 08:05AM
Feb-02-22 05:38PM
Jan-25-22 08:05AM
Jan-19-22 08:05AM
Jan-12-22 10:35AM
Jan-04-22 08:35AM
Dec-22-21 08:05AM
Dec-15-21 08:05AM
Dec-09-21 08:05AM
Nov-29-21 04:15PM
Nov-24-21 06:49AM
Nov-23-21 10:30PM
Nov-13-21 11:00AM
Nov-10-21 08:05AM
Nov-04-21 02:30PM
Nov-03-21 08:05AM
Oct-15-21 08:41AM
Oct-12-21 12:00PM
Oct-07-21 08:05AM
Oct-05-21 08:05AM
Sep-28-21 08:05AM
Sep-21-21 08:05AM
Sep-13-21 08:05AM
Sep-08-21 08:05AM
Aug-26-21 09:57AM
Aug-13-21 08:05AM
Aug-11-21 08:05AM
Aug-03-21 05:34PM
Jul-07-21 08:05AM
Jul-02-21 05:04AM
Jun-14-21 08:05AM
Jun-08-21 08:05AM
May-27-21 08:05AM
May-18-21 06:15AM
May-14-21 08:05AM
May-12-21 08:05AM
Mar-31-21 09:23AM
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dagnon TerryChief Operations OfficerApr 20Sale1.14520,000590,200653,058Apr 21 09:05 PM
Evanson JeffChief Commercial OfficerJan 20Sale1.11267,000296,370745,975Jan 24 08:08 PM
Evanson JeffChief Commercial OfficerJan 19Sale1.22103,255125,9711,012,975Jan 19 08:05 PM
Evanson JeffChief Commercial OfficerJan 18Sale1.2533,73842,1721,116,230Jan 19 08:05 PM
Evanson JeffChief Commercial OfficerJan 17Sale1.3127,16235,5821,149,968Jan 19 08:05 PM
Sukhtian Faisal GhiathDirectorOct 07Buy1.2930,00038,70068,000Oct 11 05:09 PM
Haddadin Yezan MuntherDirectorOct 07Buy1.273,6004,57263,343Oct 11 05:05 PM
Haddadin Yezan MuntherDirectorOct 06Buy1.2929,74338,36859,743Oct 11 05:05 PM
HILZINGER KURT JDirectorOct 05Buy1.2315,66219,264473,117Oct 05 04:43 PM
HILZINGER KURT JDirectorOct 04Buy1.2995,541123,248457,455Oct 05 04:43 PM
HILZINGER KURT JDirectorOct 03Buy1.2541,79852,248361,914Oct 03 05:19 PM
HILZINGER KURT JDirectorSep 30Buy1.2633,19941,831320,116Oct 03 05:19 PM
HILZINGER KURT JDirectorSep 29Buy1.1913,80016,422286,917Oct 03 05:19 PM